(acquired by IBM)
|$2.18 to $73.20||3487%|
|$2.35 to $24.08||925%|
|Cellstar||$1.44 to $13.50||837%|
|Iomega||$3.25 to $13.90||328%|
|Nanophase||$3.75 to $16.75||347%|
|Immunomedics||$1.44 to $29.12||1922%|
|Total Renal Care||$3.12 to $26.95||741%|
|Voxware||$ .90 to $10.31||1046%|
|Corvas||$3.00 to $23.25||675%|
|Cytogen||$2.12 to $17.50||725%|
|Verilink||$3.00 to $14.62||387%|
|GeneLabs||$2.31 to $10.72||364%|
WE CLOSED NEOS THERAPEUTICS AT $3.60 FOR A 71% GAIN!
WE ALSO CLOSED CONFORMIS, INC. AT $2.33 FOR A 66% GAIN!
The late-March Newsletter is now live and features even two more small biotech's. One is a BUY of SIX ANALYSTS that trades at around $2 and has a collaboration with Takeda Pharmaceuticals; while the other trades at around $3.80 and is a CHANNELED STOCK PICK.
The next Newsletter will also feature two more biotech's! One is rated a BUY OF FIVE ANALYSTS and focuses on urology and sleep disorders and trades at around $1.50; while the other trades at around $3.50 and is a BUY OF SEVEN ANALYSTS and focuses on treating infectious diseases.
"I cannot thank you enough for your excellent newsletter... I do believe I have found a new hobby (and a well paying one, at that), thanks to you!"
— B.K. (Contractor in Saudi Arabia)